Replies to post #1137 on Evoke Pharma Inc. (EVOK)

[Martin11]

I like this part of the paragraph in the news.

"The number of shares of common stock to be outstanding after this offering is based on 12,350,360 shares outstanding as of September 30, 2016 and excludes:

1,275,624 shares of common stock issuable upon the exercise of options outstanding as of September 30, 2016, at a weighted average exercise price of $4.04 per share; 3,323,876 shares of common stock issuable upon the exercise of warrants outstanding as of September 30, 2016, at a weighted average exercise price of $3.29 per share; and

666,264 shares of common stock reserved for future issuance under our 2013 equity incentive award plan and our 2013 employee stock purchase plan as of September 30, 2016.


Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriter of its option to purchase up to an additional shares of our common stock.
Dont worry this will trade in and around $10 to $15 range when FDA approves the drug for markting.

[Lone Wolf]

Looking like the lucky ones were those that grabbed some $3's. They were quick to go through the actual filing I'm sure.